Drug Trial Radar · NCT00590070
THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction
Last checked: Nov 20, 2026Latest source record: Mar 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Jan 2008
Primary completion
Jun 2011
Study completion Sep 2011
Sponsor
- Lead sponsor
- Catholic University of the Sacred HeartAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 10, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in acute myocardial infarction is described in up to 40% of cases. This event is associated with a worse prognosis at follow up and an unfavourable left ventricular remodelling . Two main pathogenetic mechanisms cause no-reflow: distal embolization and ischemia-reperfusion injury. Due to the multifactorial pathogenesis of no-reflow during acute MI a combined mechanic and pharmacologic approach is believed to offer a better solution for achieving optimal microvascular reperfusion. Thus, in this randomized study we will assess the effect of nitroprusside or adenosine in adjunct to current best therapy (thrombus aspiration and IIb-IIIa antagonists) for ST elevation MI using ST segment resolution on standard 12 leads ECG as primary endpoint of myocardial reperfusion.
Conditions
- Myocardial Infarction
Interventions
adenosineDrug
Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
nitroprussideDrug
Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
placeboDrug
33 cc of heparinized saline given in 2 minutes as slow bolus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of major adverse cardiac eventsTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dipartimento Medicina Cardiovascolare
Rome, Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.